SynOx Advances $75M Phase 3 Trial for Rare Tumor Treatment
Could SynOx's $75M Phase 3 Trial Be the Next Big Leap in TGCT Treatment?
Source: biopharma-reporter.com
📰 Bioqube Ventures News
Bioqube Ventures News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bioqube Ventures. Real-time updates on events, politics, business and more.
SynOx Therapeutics raises $75m in fresh funding round
Iirsh and UK firm has raised more than $100 million to date
Source: irishtimes.com
Biopharma firm SynOx Therapeutics raises $75m in funding round
Biopharmaceutical company SynOx Therapeutics has raised $75m (€70.5m) to continue its development of a treatment for Tenosynovial Giant Cell Tumour (TGCT).
Source: independent.ie
Bicara Therapeutics Raises $165M in Series C Financing
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
United States Claire Mazumdar Life Sciences Innovations Rise Fund Bicara Therapeutics Sciences Innovations
Source: finsmes.com
Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic
Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, announced today an EUR 8.5 million seed round extension, adding MRL Ventures Fund as a
Source: finanznachrichten.de
Anavo Therapeutics Extends Seed Round to €28M
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
Bicara Therapeutics, a spinout of Kiran Mazumdar-Shaw's Biocon, raises $108m
The Series B round was co-led by Red Tree Venture Capital and RA Capital Management.
Bicara Therapeutics Kiran Mazumdar Shaw Founded Biocon Red Tree Venture Capital Eight Roads Ventures F Prime Capital Piper Heartland Healthcare Capital
Source: dealstreetasia.com
Bicara Therapeutics Raises $108M in Series B Financing
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
Strong investment continues for developer of Autoimmune Therapies
Biotech start-up Tridek-One focused on research and development of CD31 agonists to restore the immune balance, has closed a €16 million ($16. Click to read more...
Source: labmate-online.com
Tridek-One bags €16M to develop auto-immune diseases candidates
Tridek-One SAS, which specializes in the R&D of CD31 agonists to restore immune balance, has closed a €16 million financing round.
France General Benoit Barteau Giuseppina Caligiuri Pureos Bioventures Klaus Breiner Advent Life Sciences
Source: labiotech.eu